Detalhe da pesquisa
1.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med;
381(16): 1535-1546, 2019 10 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31562797
2.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med;
377(14): 1345-1356, 2017 10 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28889792
3.
Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone.
Cytotherapy;
20(6): 851-860, 2018 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29754770
4.
Dabrafenib-trametinib combination in 'field-practice': an Italian experience.
Future Oncol;
14(20): 2045-2052, 2018 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30081673
5.
IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia.
J Transl Med;
13: 229, 2015 Jul 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26174551
6.
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
J Transl Med;
12: 262, 2014 Sep 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25245327
7.
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
J Transl Med;
12: 209, 2014 Jul 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25053129
8.
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.
J Neurooncol;
118(1): 109-16, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24532241
9.
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
Eur J Cancer;
199: 113531, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38271746
10.
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Nat Commun;
15(1): 146, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38167503
11.
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
J Transl Med;
11: 135, 2013 May 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23725550
12.
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.
Front Oncol;
13: 1107307, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36845751
13.
Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.
Tumori;
109(6): 537-545, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37417313
14.
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
J Clin Oncol;
41(23): 3917-3929, 2023 08 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37307514
15.
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Eur J Cancer;
191: 113246, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37549531
16.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
J Clin Oncol;
41(2): 212-221, 2023 01 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36049147
17.
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
Cancer Treat Rev;
110: 102463, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36099854
18.
Stability Program in Dendritic Cell Vaccines: A "Real-World" Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center.
Vaccines (Basel);
10(7)2022 Jun 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35891165
19.
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
J Clin Oncol;
40(2): 127-137, 2022 01 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34818112
20.
Melanoma metastasis mimicking gastric cancer: a challenge that starts from diagnosis.
Therap Adv Gastroenterol;
14: 1756284821989559, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33717209